ALLMedicine™ Hemophilia B Center

May 25th, 2021 - Nonacog alfa (recombinant factor IX [FIX]) is approved in China for the control and prevention of bleeding events in patients with hemophilia B. This was the first study to assess prophylaxis and on-demand therapy with recombinant FIX replacement ...

May 11th, 2021 - Coagulation factor IX (FIX) is a serine protease zymogen involved in the intrinsic blood coagulation pathway, and its deficiency causes Hemophilia B. Zebrafish has three f9 genes, and the ortholog to human F9 is unknown. To identify the zebrafish ...

May 7th, 2021 - Hemophilia A and hemophilia B are X-linked inherited bleeding disorders caused by a deficiency of coagulation factor VIII and IX, respectively. Standard of care is prophylactic factor replacement therapy; however, the development of neutralizing a...

Apr 25th, 2021 - Adeno-associated virus (AAV)-mediated gene therapy is a novel treatment promising to reduce morbidity associated with hemophilia. While multiple clinical trials continue to evaluate efficacy and safety, limited cost-effectiveness data have been pu...

Apr 8th, 2021 - Hemophilia B is a rare congenital blood disorder characterized by factor IX deficiency. Clinical profiles of hemophilia B range from mild to severe forms of the disease. The objective of this study was to characterize the economic burden associate...

Dec 4th, 2020 - Haemophilia B (HB) is less well studied than haemophilia A (HA); despite similarities between the two inherited bleeding disorders, important differences remain that require further research.

Nov 7th, 2020 - Hemophilia is the most common X‐linked bleeding disorder, affecting over 1 million individuals throughout the world. Patients are subclassified into mild, moderate and severe disease based on per cent factor activity level.

Oct 13th, 2020 - Hemophilia is an inherited disease that requires a different approach in order to evaluate, monitor and treat patients. Despite the great advances in therapeutic agents that have emerged, reports on the impact of monitoring outcomes on treatment d...

Aug 2nd, 2020 - This new edition of the World Federation of Hemophilia (WFH) guidelines for the management of hemophilia comes at an exciting time in the evolution of the diagnosis and treatment of this condition. Since the publication of the second edition in 20...

Jan 23rd, 2017 - Prior to the availability of clotting factor concentrates, the natural history of arthropathy in severe haemophilia was well described, with recurrent bleeds into joints leading to progressive joint damage and ultimate destruction with associa...

May 25th, 2021 - Nonacog alfa (recombinant factor IX [FIX]) is approved in China for the control and prevention of bleeding events in patients with hemophilia B. This was the first study to assess prophylaxis and on-demand therapy with recombinant FIX replacement ...

May 11th, 2021 - Coagulation factor IX (FIX) is a serine protease zymogen involved in the intrinsic blood coagulation pathway, and its deficiency causes Hemophilia B. Zebrafish has three f9 genes, and the ortholog to human F9 is unknown. To identify the zebrafish ...

May 11th, 2021 - As the burden of hemophilia B in patients increases from mild to severe forms of the disease, the already high economic cost of treatment rises significantly, according to a large retrospective database study. Researchers developed four profile ca...

May 7th, 2021 - Hemophilia A and hemophilia B are X-linked inherited bleeding disorders caused by a deficiency of coagulation factor VIII and IX, respectively. Standard of care is prophylactic factor replacement therapy; however, the development of neutralizing a...

Apr 25th, 2021 - Adeno-associated virus (AAV)-mediated gene therapy is a novel treatment promising to reduce morbidity associated with hemophilia. While multiple clinical trials continue to evaluate efficacy and safety, limited cost-effectiveness data have been pu...

May 11th, 2021 - As the burden of hemophilia B in patients increases from mild to severe forms of the disease, the already high economic cost of treatment rises significantly, according to a large retrospective database study. Researchers developed four profile ca...

Dec 17th, 2020 - NEW YORK (Reuters Health) - An investigational gene therapy for hemophilia B substantially increased production of the blood-clotting protein factor IX and reduced the number of bleeding episodes and need for prophylactic therapy in a phase-3 tria...

Dec 4th, 2020 - Haemophilia B (HB) is less well studied than haemophilia A (HA); despite similarities between the two inherited bleeding disorders, important differences remain that require further research.

Nov 7th, 2020 - Hemophilia is the most common X‐linked bleeding disorder, affecting over 1 million individuals throughout the world. Patients are subclassified into mild, moderate and severe disease based on per cent factor activity level.

Oct 21st, 2020 - Hemophilia A is an inherited deficiency of FVIII and an X-linked recessive disorder. Hemophilia B, another recessive disorder, is characterized by a deficiency in factor IX. Hemophilia C is an autosomal recessive disorder in which patients are def...